REGN 2477

Drug Profile

REGN 2477

Alternative Names: REGN2477

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action Activin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibrodysplasia ossificans progressiva; Musculoskeletal disorders

Most Recent Events

  • 10 Feb 2017 REGN 2477 receives Orphan Drug status for Fibrodysplasia ossificans progressiva in USA before February 2017
  • 09 Jan 2017 Phase-I clinical trials in Musculoskeletal disorders (Combination therapy, In volunteers) in New Zealand (unspecified route) (NCT02943239)
  • 09 Jan 2017 Phase-I clinical trials in Musculoskeletal disorders (In volunteers) in New Zealand (unspecified route) (NCT02943239)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top